Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Gareth D. James"'
Autor:
Giuseppe Viale, Mark Basik, Naoki Niikura, Eriko Tokunaga, Sara Brucker, Frédérique Penault-Llorca, Naoki Hayashi, Joo Hyuk Sohn, Rita Teixeira de Sousa, Adam M. Brufsky, Ciara S. O’Brien, Fernando Schmitt, Gavin Higgins, Della Varghese, Gareth D. James, Akira Moh, Andrew Livingston, Victoria de Giorgio-Miller
Publikováno v:
Cancer Research. 83:HER2-15
Background: About 60% of breast cancers (BCs) traditionally categorized as HER2 negative (HER2-neg; immunohistochemistry [IHC] 0, IHC 1+ or IHC 2+/in situ hybridization [ISH]–) express low levels of HER2 (HER2-low; IHC 1+ or IHC 2+/ISH–; Schettin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::45b1024053df161652e7d88213950f9b
https://doi.org/10.1158/1538-7445.sabcs22-her2-15
https://doi.org/10.1158/1538-7445.sabcs22-her2-15
Autor:
Andreas Spitzmüller, Ansh Kapil, Anatoliy Shumilov, Jessica Chan, Lemonia Konstantinidou, Zonera Hassan, Mark Gustavson, Danielle Carroll, Della Varghese, Gareth D. James, Akira Moh, Andrew Livingston, Victoria de Giorgio-Miller
Publikováno v:
Cancer Research. 83:P6-04
Background HER2 directed therapies for breast cancer (BC) rely on accurate estimation of HER2 expression by pathologist scoring of immunohistochemically (IHC) stained tissue according to ASCO/CAP guidelines Emerging HER2-targeted antibody drug conjug
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7593a06f4fd26b89c205a0917d57a494
https://doi.org/10.1158/1538-7445.sabcs22-p6-04-03
https://doi.org/10.1158/1538-7445.sabcs22-p6-04-03
Autor:
Mark Kristof Farkas, Harriet Kang, Andras Fogarasi, Ali Bozorg, Gareth D. James, Walter Krauwinkel, Diego Morita, Edgar Will, Jan‐Peer Elshoff
Publikováno v:
Epilepsia. 63(4)
To evaluate the pharmacokinetics, safety, and tolerability of brivaracetam (BRV) as 15-min intravenous (IV) infusion and bolus (≤2-min injection).EP0065 (ClinicalTrials.gov: NCT03405714) was a Phase 2, multicenter, open-label trial in patients ≥1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::175ac6ee4eff10cd7327ad231205b62e
https://pubmed.ncbi.nlm.nih.gov/35196395
https://pubmed.ncbi.nlm.nih.gov/35196395
Autor:
Giuseppe Viale, Naoki Niikura, Eriko Tokunaga, Olga Aleynikova, Naoki Hayashi, Joohyuk Sohn, Ciara O'Brien, Gavin Higgins, Della Varghese, Gareth D James, Akira Moh, Nana Scotto
Publikováno v:
Journal of Clinical Oncology. 40:1087-1087
1087 Background: Approximately 50% of BCs traditionally categorized as HER2 negative (HER2-neg) express low levels of HER2 (IHC 1+ or IHC 2+/ISH-; Miglietta, NPJ Breast Cancer 2021). HER2-targeted therapies for HER2-low metastatic BC (mBC) are under
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9f13c7741235eb42411ed7a5102ec1fd
https://doi.org/10.1200/jco.2022.40.16_suppl.1087
https://doi.org/10.1200/jco.2022.40.16_suppl.1087
Autor:
Gareth D. James
Publikováno v:
International Political Science Abstracts. 68:149-149
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d9de430967ba06333de982d3293a7118
https://doi.org/10.1177/0020834518068001147
https://doi.org/10.1177/0020834518068001147